Climb Bio shares additional CLYM116 Phase 1 data with ~33-day half-life
Climb Bio and Mabworks reported additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, presented at ASN Kidney Week 2026. The data show an estimated half-life of about 33 days and, at 12 weeks after an 800 mg dose, reductions of about 70% in Gd-IgA1 and about 60% in IgA. The filing contains no revenue or earnings figures, and the next key milestone remains initial data from the NAVIGATE-2 Phase 2 trial in the first half of 2027.
Key points
- Estimated half-life of approximately 33 days, based on the 800 mg and 320 mg multiple-ascending dose cohorts
- Free APRIL suppression of 90% or more through 12 weeks after a single subcutaneous dose of 480 mg or higher
- About 70% Gd-IgA1 and about 60% IgA reduction at 12 weeks after a single 800 mg dose, the NAVIGATE-2 loading dose
- Injection site reactions in 5 of 88 participants, all Grade 1; initial NAVIGATE-2 data expected in the first half of 2027
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.